• Publications
  • Influence
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
BACKGROUND Heparin-induced thrombocytopenia, defined by the presence of heparin-dependent IgG antibodies, typically occurs five or more days after the start of heparin therapy and can be complicatedExpand
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.
The combination of a score < or =4.0 by the authors' simple clinical prediction rule and a negative SimpliRED D-Dimer result may safely exclude PE in a large proportion of patients with suspected PE. Expand
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical outcome at 90 days. Expand
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occur in arrhythmic mortality with ICD therapy compared with amiodarone; this reduction did not reach statistical significance. Expand
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding. Expand
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
Prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a myocardial infarction, and is associated with a reduction in the rate of death due to arrhythmia, that was offset by an increase in the rates of death from nonarrhythmic causes. Expand
Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism
The optimal strategy for investigating patients with suspected pulmonary embolism should combine clinical assessment, ventilation-perfusion scanning, and venous ultrasonography of the lower extremities, and the group developed a useful clinical model by reviewing the literature and coming to a consensus on a scoring system. Expand
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome. Expand
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg
The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other, and there is a 28% reduction in the relative risk of death with the ICD that is due almost entirely to a 50% reduced in arrhythmic death. Expand
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Patients with a first episode of idiopathic venous thromboembolism should be treated with anticoagulant agents for longer than three months, according to a prespecified interim analysis of efficacy. Expand